Immune Checkpoint Inhibitors: all 7,814 studies that test it

Page 15 of 79. Open to participants first (2,629), then studies with results posted, then the rest; newest registration first within each.

• Short-course Radiotherapy Combined With CapeOx and PD-1 Inhibitor After Local Excision for High-risk Early Rectal Cancer (TORCH-LE)RecruitingNCT06455124Phase 2
• Nituzumab Plus Serplulimab Combined With SBRT in Cervical CancerRecruitingNCT06455072Phase 2
• Efficacy and Safety of AK104 Combined With Chemotherapy and Recombinant Human Adenovirus 5 Injection in Cervical CancerRecruitingNCT06455046Phase 2
• Adjuvant Adebrelimab Plus Apatinib for Participants With HCC at High-risk of Recurrence After Curative ResectionRecruitingNCT06454578Phase 2
• Phase Ib/II Clinical Study of Adebrelimab in Combination With Decitabine, Albumin-bound Paclitaxel, and Gemcitabine for the First-line Treatment of Metastatic Pancreatic CancerRecruitingNCT06454448Phase 1/2
• Neoadjuvant Immunotherapy Plus Chemotherapy in Borrmann Type 4 and Large Type 3 Gastric CancerRecruitingNCT06451211Phase 2
• Neoadjuvant Chemo-Immunotherapy and Surgical Resection in Locally Advanced Non-small Cell Lung Cancer With N3 Lymph Node or Other High Risk FeaturesRecruitingNCT06449313Phase 2
• Cemiplimab and Cetuximab Prior Salvage Surgery in Patients With Recurrent Oral Cavity and HPV-negative Oropharyngeal Squamous Cell CarcinomaRecruitingNCT06448026Phase 2
• Low-dose Radiation Combined With Neoadjuvant Immunochemotherapy for Esophageal Squamous Cell CarcinomaRecruitingNCT06446726Phase 2
• Study of QLS31905 and/or QL1706 Combination With Chemotherapy in the Advanced Malignant Solid TumorsNot yet recruitingNCT06446388Phase 2
• Adebrelimab Plus Chemotherapy, Bevacizumab and Fluzoparib in Platinum-Sensitive Relapsed Ovarian CancerNot yet recruitingNCT06446206Phase 2
• Phase II Study of the Combination of Durvalumab (MEDI4736) (PDL1 Inhibitor) and Olaparib (PARP Inhibitor) in Advanced Cholangiocarcinoma After Initial Chemotherapy and Durvalumab (BIL-PPP)RecruitingNCT06441747Phase 2
• Toripalimab Plus Anlotinib for the Maintenance of Extensive Stage Small CellNot yet recruitingNCT06441344Phase 3
• Durvalumab + Intraductal Radiofrequency Ablation (ID-RFA) in Extra- and Intrahepatic CholangiocarcinomaRecruitingNCT06440993Phase 2
• Pembrolizumab Plus CA-4948 for the Treatment of Patients With Progressive Metastatic Urothelial Cancer Despite Prior ImmunotherapyRecruitingNCT06439836Phase 1
• Adjuvant Treatment With Serplulimab，Trastuzumab and SOX in the HER-2 Positive GC/GEJCNot yet recruitingNCT06439550Phase 2
• Phase I/II Trial of Pemigatinib in Combination With Atezolizumab and Bevacizumab for Treatment of Advanced Cholangiocarcinoma With FGFR2 FusionRecruitingNCT06439485Phase 1/2
• A Study of BL-B01D1+PD-1 Monoclonal Antibody in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma and Other Solid TumorsRecruitingNCT06437522Phase 2
• A Study of BL-B01D1+PD-1 Monoclonal Antibody in Patients With Extensive-stage Small Cell Lung CancerRecruitingNCT06437509Phase 2
• Hypofractionated Radiotherapy +Chemotherapy+ Camrelizumab as Neoadjuvant Therapy for Pancreatic CancerRecruitingNCT06435260Phase 2
• Study of Treatment With Sacituzumab and Zimberelimab for Patients With Lung Cancer Confined to the Chest and Previously Operated on Who Were Not Disease-free.RecruitingNCT06431633Phase 3
• Neoadjuvant Comprehensive Treatment for Unresectable Esophageal CancerRecruitingNCT06430658Phase 2
• Anlotinib Combined With Benmelstobart for Advanced PheochromocytomaNot yet recruitingNCT06429397Phase 2
• A Study of Cadonilimab（AK104）Combined With Standard Treatment for Function Preservation in Urinary System TumorsNot yet recruitingNCT06427057Phase 2
• Neoadjuvant Cadonilimab Combined With Anlotinib in Locally Advanced Resectable Esophageal Squamous Cell CarcinomaNot yet recruitingNCT06426797Phase 2
• ctDNA-MRD Guided Consolidation Toripalimab in Stage IB-IIIA NSCLCRecruitingNCT06426511Phase 2
• A Study Comparing Neoadjuvant Chemoimmunotherapy and Immuno-consolidationafter Compared With Immunoconsolidation After Radical Chemoradiotherapy for Stage III Potentially Resectable NSCLCRecruitingNCT06424899Phase 2
• Cadonilimab Plus Chemotherapy as First-line Treatment for PD-L1 Negative NSCLCRecruitingNCT06424821Phase 2
• A Trial of AK104 or AK112 in Combination With Axitinib in Patients With Metastatic Mucosal MelanomaEnrolling by invitationNCT06424626Phase 1
• Fruquintinib Plus Camrelizumab and HAIC in the Treatment of Non-MSI-H Advanced Colorectal CancerNot yet recruitingNCT06423937Phase 2
• A Single-arm Phase II Clinical Study of the Efficacy and Safety of Camrelizumab Combined With GEMOX for Unresectable GBCsRecruitingNCT06423170Phase 2
• Sequential Tegafur-gimeracil-oteracil Potassium Capsule (s-1) and Serplulimab Following Concurrent Chemoradiotherapy for Esophageal Squamous Cell CarcinomaRecruitingNCT06422858Phase 2
• Measuring if Immunotherapy Plus Chemotherapy is Better Than Chemotherapy Alone for Patients With Aggressive Poorly Differentiated SarcomasRecruitingNCT06422806Phase 3
• A Prospective, Single-arm, Phase II Clinical Trial to Evaluate the Efficacy and Safety of Tafolecimab and Sintilimab Combined With Chemotherapy in Patients With Advanced or Metastatic Driver Gene-negative Non-small Cell Lung Cancer After Failure of First-line Immunotherapy.RecruitingNCT06421298Phase 2
• Maintenance Durvalumab (MEDI4736) and Olaparib (AZD2281) After Standard 1st Line Treatment (Carboplatin/Cisplatin, Etoposide, Durvalumab) in HRD Positive Extensive Disease (ED) Small-cell Lung Cancer (SCLC)Enrolling by invitationNCT06419179Phase 2
• Neoadjuvant PD-1 Inhibitor and EGFR Inhibitor in Locally Advanced Cutaneous Squamous Cell CarcinomaNot yet recruitingNCT06418724Phase 2
• Adebrelimab Plus Apatinib and Etoposide for the Treatment of HER2-Negative Breast Cancer Brain MetastasisRecruitingNCT06418594Phase 2
• Durvalumab With Carboplatin and Etoposide Chemotherapy in Pulmonary Large-cell Neuroendocrine Carcinoma (LCNEC)RecruitingNCT06418087Phase 2
• A Trial of SHR-A2102 With or Without Antitumor Therapy in Advanced Solid TumorsRecruitingNCT06417554Phase 1/2
• Study of Cadonilimab Combined With Chemotherapy in Recurrent / Refractory Pleural MesotheliomaNot yet recruitingNCT06416930Phase 2
• A Study of Paclitaxel Combined With Apatinib and Adebrelimab in Gastric/Gastroesophageal Junction AdenocarcinomaRecruitingNCT06415669Phase 2
• Surufatinib Combined With Tislelizumab in Advanced Lung Cancer With Neuroendocrine DifferentiationNot yet recruitingNCT06414915Phase 2
• A First-In Human (FIH) Study to Find Out How Well REGN10597 Medicine Given Alone or in Combination With Cemiplimab Works in Adult Participants Who Have Cancer With Tumors That Have Spread in Their BodyRecruitingNCT06413680Phase 1/2
• Sintilimab After Concurrent Chemoradiotherapy in Elderly Patients With Esophageal Squamous Cell CarcinomaRecruitingNCT06413342Phase 2
• Nimotuzumab Combined With ICIs for the Treatment of Advanced Liver Cancer After First Line Treatment FailureRecruitingNCT06413017Phase 2
• A Phase II Study of SSGJ-707 Combination Therapy in Advanced NSCLC PatientsRecruitingNCT06412471Phase 2
• A Multicenter Phase 1b/2 Study of Adagrasib, Cetuximab, and Cemiplimab for Metastatic Colorectal Cancer Harboring KRAS G12C MutationsRecruitingNCT06412198Phase 1/2
• KRAS-Targeted Vaccine Combined With Balstilimab and Botensilimab for Patients With Stage IV MMR-p Colorectal Cancer and Pancreatic Ductal CancerRecruitingNCT06411691Phase 1
• SHR-A1811 in Combination With Adebrelimab for the Treatment of HER2 Low-expressing Metastatic Breast CancerRecruitingNCT06411457Phase 2
• Safety and Efficacy of Pembrolizumab in Combination With FLOT About Gastroesophageal Junction Cancer:Not yet recruitingNCT06411171Phase 3
• Safety and Modulation of Adaptive Immunity by Iscador® Qu Viscum Album Extract in Patients With Advanced, Recurrent or Metastatic Cancers Treated With Immune Checkpoint InhibitorsRecruitingNCT06408688Phase 4
• Neoadjuvant Pembrolizumab, Carboplatin and Paclitaxel in Triple-negative Breast CancerNot yet recruitingNCT06407310Phase 2
• A Phase II Clinical Study of Cadonilimab in Treatment-naïve or Relapsed Extensive Small Cell Lung CancerRecruitingNCT06406673Phase 2
• Cadonilimab in Combination With Lenvatinib and Hepatic Arterial Infusion Chemotherapy (HAIC) for the Treatment of Unresectable Hepatocellular CarcinomaRecruitingNCT06406634Phase 2
• NALIRI-XELOX+AK104 for First-line Treatment of Advanced PDACRecruitingNCT06405490Phase 2
• A Study of BL-B01D1 + PD-1 in Patients With Locally Advanced or Metastatic Urothelial CarcinomaRecruitingNCT06405425Phase 2
• QL1706 Plus Chemotherapy as Neoadjuvant Therapy in Early High-Risk ER+/HER2- Breast CancerNot yet recruitingNCT06404463Phase 2
• Safety and Efficacy of Neoadjuvant Immunochemotherapy in Elderly Patients With Resectable Esophageal CancerRecruitingNCT06403878Phase 2
• SBRT, Chemotherapy, and AK112 Neoadjuvant Therapy for Luminal-type Breast CancerRecruitingNCT06402435Phase 2
• SBRT, Chemotherapy, and AK104 Neoadjuvant Therapy for Triple-negative Breast Cancer (TNBC)RecruitingNCT06401005Phase 2
• CBM588 Capsules in Combination With Nivolumab and Ipilimumab for the Treatment of Advanced Stage Kidney CancerRecruitingNCT06399419Phase 1
• FIRST-NEC (GFPC 01-2022) - Combination of Durvalumab With Etoposide and PlatinumRecruitingNCT06393816Phase 2
• Concurrent Chemoradiotherapy Followed by PD-1 Inhibitor in Advanced Cervical CancerRecruitingNCT06391190Phase 1/2
• Immunosensitized Radiotherapy Combined With Evoximab (AK112) and Chemotherapy Neoadjuvant Therapy for Stage II-III Non-small Cell Lung CancerNot yet recruitingNCT06391008Phase 2
• Organ Preservation With Tislelizumab and Total Neoadjuvant Therapy in Patients With Low Rectal Cancer: RELIEVE -01 StudyNot yet recruitingNCT06390982Phase 2
• A Study to Evaluate the Safety, Tolerability and Preliminary Efficacy of SSGJ-705 Monotherapy in Patients with Advanced Malignant TumorsRecruitingNCT06390774Phase 1
• A Phase 2, Open Label Study of PEmigatinib and REtifanlimab in Advanced Dedifferentiated LIposarcoma (PERELI)RecruitingNCT06389799Phase 2
• A Study of CHS-1000 in Participants With Advanced or Metastatic Solid TumorsNot yet recruitingNCT06389526Phase 1
• HAIC+Adebrelimab+Lenvatinib for Conversion Treatment of Potentially Resectable, Locally Advanced Biliary Tract CancerNot yet recruitingNCT06389500Phase 2
• Phase II Study of Moderate-dose Hypofractionated RT Combined With Pembrolizumab for HCC With Diffuse Tumor ThrombosisRecruitingNCT06389422Phase 2
• To Evaluate the Efficacy and Safety of Disitamab Vedotin Combined With Toripalimab Sequential Chemotherapy as Neoadjuvant Treatment in Patients With HR-positive, HER2-low Breast CancerRecruitingNCT06389006Phase 2
• ICI Rechallenge for Advanced NSCLC With Long-Term Response to First-Line ICIRecruitingNCT06388031Phase 2
• Genomic Biomarker-guided Neoadjuvant Therapy for Prostate Cancer (SEGNO)RecruitingNCT06387056Phase 2
• TOP 2301: Neoadjuvant Chemo for NSCLCRecruitingNCT06385262Phase 2
• Neoadjuvant Triple Therapy for (Borderline) Resectable Pancreatic Cancer (PREOPANC-5)RecruitingNCT06384560Phase 1/2
• Safety,Tolerability, Pharmacokinetics, and Efficacy of YL211 in Patients With Advanced Solid TumorsRecruitingNCT06384352Phase 1
• Safety and Efficacy of XELOX Combined With Sintilimab and Lenvatinib in Advanced AFP-positive Gastric Cancer PatientsRecruitingNCT06383559Phase 2
• A Phase I/II Trial of UCB4594 in Participants With Advanced CancerRecruitingNCT06380816Phase 1/2
• Radiation Therapy Followed by Tislelizumab and Anlotinib Aeoadjuvant/Adjuvant Therapy for Stage II-IIIA NSCLCRecruitingNCT06379087Phase 2
• A Study of BV-AVD in People With Bulky Hodgkin LymphomaRecruitingNCT06377566Phase 2
• MT2022-60: Ph 2 Study of Pembro+ BEAM With ASCT for Relapsed Hodgkin LymphomaRecruitingNCT06377540Phase 2
• Linperlisib Combined With Camrelizumab and Pegaspargase in Advanced or Relapsed/Refractory NK/T-cell LymphomaRecruitingNCT06376721Phase 1/2
• Precision Medicine in Patients With Unresectable CholAngiocarcinoma: RadioEmbolization and Combined Biological TherapyRecruitingNCT06375915Phase 2
• A Single Arm, Single Centered Phase II Trial on the Combination of Adebrelimab, Surufatinib and Irinotecan Liposome-based HAIC in Advanced iCCNot yet recruitingNCT06375642Phase 2
• HAIC Combined With PD-L1 Plus Regorafenib in the Treatment of Advanced Hepatocellular Carcinoma After Immunotherapy FailureNot yet recruitingNCT06375317Phase 2
• PD-L1/PD-1 Inhibitors Plus Chemotherapy Versus Chemotherapy Alone for the Neoadjuvant Treatment of Limited-stage SCLCNot yet recruitingNCT06375109Phase 2
• Tislelizumab Combined With Neoadjuvant Chemotherapy Used in the Perioperative Treatment.Not yet recruitingNCT06374901Phase 2
• Efficacy of Pembrolizumab and Lenvatinib in Patients With Anaplastic Thyroid CancerRecruitingNCT06374602Phase 2
• SHR-8068 Combined With Adbelizumab and BP102 in the Treatment of Advanced Colorectal CancerNot yet recruitingNCT06373133Phase 1/2
• Study of ZG005 in Combination With Etoposide and Cisplatin in Participants With Advanced Neuroendocrine Carcinoma.RecruitingNCT06372626Phase 1/2
• Trial for Treatment of High Risk BC With Two Sequences of Neoadjuvant Chemotherapy With PembrolizumabNot yet recruitingNCT06371807Phase 2
• Durvalumab Combined With Chemoradiotherapy for Limited Stage Small Cell Lung Cancer (Camel-01)RecruitingNCT06371482Phase 2
• A Study on the Efficacy and Safety of Oral All-trans Retinoic Acid Combined With Toripalimab in TNBC.RecruitingNCT06371274Not applicable
• A Study of AK104+Lenvatinib in Combination With Transarterial Chemoembolization (TACE) Versus TACE in Participants With Incurable/Non-metastatic Hepatocellular CarcinomaRecruitingNCT06371157Phase 3
• Newly Emerging Immunotherapy for Pancreatic Cancer TreatmentNot yet recruitingNCT06370754Phase 1/2
• Neoadjuvant Chemotherapy Plus Sequential Immune Checkpoint Inhibitor (ICI) Therapy in Locally Advanced Colon CancerRecruitingNCT06368141Phase 2
• Cadonilimab Combined With Chemotherapy as First or Second Line Treatment in Recurrent or Metastatic Triple Negative Breast CancerRecruitingNCT06367088Phase 2
• A Trial of Cadonilimab With Adriamycin in Patients With Advanced Soft Tissue SarcomaRecruitingNCT06367075Phase 2
• A Study of IMC-001 In Patients With Metastatic Or Locally Advanced TMB-H Solid TumorRecruitingNCT06365840Phase 2
• DISCERN: Dual Versus Single ICB in PDL-1 Negative NSCLCRecruitingNCT06364917Phase 2

← Immune Checkpoint Inhibitors overview